Skip to main content

Table 2 Factors associated with MVC prescription after a tropism test

From: Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study

  Factors associated with MVC prescription
Univariate Multivariate
OR (CI 95%) p OR (CI 95%) p
Period of test:
Before 2011 4.16 (2.51–6.89) < 0.01 3.65 (2.17–6.13) < 0.01
After 2011 1   1  
Age (years):   0.26   
< 35 0.60 (0.25–1.45)    
35–43 0.68 (0.35–1.32)    
44–51 1.1 (0.63–1.93)    
> 51 1    
Time between ART initiation and tropism (years):   0.03   
< 5 0.50 (0.27–0.92)    
5–10 0.88 (0.49–1.58)    
> 10 1    
Number of previous ART regimens:   < 0.01   
< 4 0.24 (0.11–0.51)   0.34 (0.15–0.74) < 0.01
4–5 0.25 (0.11–0.55)   0.32 (0.14–0.74) < 0.01
6–10 0.39 (0.19–0.79)   0.46 (0.22–0.97) 0.04
> 10 1   1  
CD4 count (/mm3):   0.02   
≤200 0.34 (0.13–0.85)    
201–500 0.86 (0.52–1.42)    
> 500 1    
Reason for tropism performance:     
Virological failure 1.95 (1.20–3.16) < 0.01 1.10 (0.62–1.98) 0.73
Other 1   1  
  1. MVC Maraviroc, ART Anti Retroviral Therapy